ATE231549T1 - Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung - Google Patents

Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung

Info

Publication number
ATE231549T1
ATE231549T1 AT97933740T AT97933740T ATE231549T1 AT E231549 T1 ATE231549 T1 AT E231549T1 AT 97933740 T AT97933740 T AT 97933740T AT 97933740 T AT97933740 T AT 97933740T AT E231549 T1 ATE231549 T1 AT E231549T1
Authority
AT
Austria
Prior art keywords
viruses
viral
recombining
aqueous suspension
medical use
Prior art date
Application number
AT97933740T
Other languages
German (de)
English (en)
Inventor
Claude Sene
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE231549T1 publication Critical patent/ATE231549T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT97933740T 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung ATE231549T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9608851A FR2751343B1 (fr) 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
PCT/FR1997/001308 WO1998002522A1 (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Publications (1)

Publication Number Publication Date
ATE231549T1 true ATE231549T1 (de) 2003-02-15

Family

ID=9494078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933740T ATE231549T1 (de) 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung

Country Status (11)

Country Link
US (2) US6451256B1 (OSRAM)
EP (1) EP0853660B1 (OSRAM)
JP (1) JP3681401B2 (OSRAM)
AT (1) ATE231549T1 (OSRAM)
AU (1) AU711409B2 (OSRAM)
CA (1) CA2232604C (OSRAM)
DE (1) DE69718612T2 (OSRAM)
DK (1) DK0853660T3 (OSRAM)
ES (1) ES2187798T3 (OSRAM)
FR (1) FR2751343B1 (OSRAM)
WO (1) WO1998002522A1 (OSRAM)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
AU773834B2 (en) * 1998-12-03 2004-06-10 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
CN1347450A (zh) * 1999-04-09 2002-05-01 阿文蒂斯药物股份有限公司 用于保存感染性重组腺病毒的组合物
FR2791999B1 (fr) * 1999-04-09 2001-09-07 Aventis Pharma Sa Composition destinee a la conservation d'adenovirus recombinants infectieux
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1284287A4 (en) * 2000-05-10 2004-10-13 Mitsubishi Pharma Corp METHOD FOR PRODUCING A VIRUS VECTOR
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
BR0306925A (pt) * 2002-01-18 2004-11-09 Schering Ag Formulações estabilizadas de adenovìrus
KR100507794B1 (ko) * 2003-02-11 2005-08-17 한미약품 주식회사 고농도 레트로 바이러스 현탁액 제조 방법
WO2005052116A2 (en) * 2003-11-19 2005-06-09 Merck & Co., Inc. Preservative-containing virus formulations
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
MX350932B (es) 2010-12-02 2017-09-26 Oncolytics Biotech Inc Formulaciones virales liquidas.
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
PL2825640T3 (pl) 2012-03-12 2016-10-31 Partie rekombinowanych adenowirusów o zmienionych końcach
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SG11201405804YA (en) 2012-03-22 2014-10-30 Crucell Holland Bv Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CN104640564B (zh) 2012-07-10 2020-08-04 特兰斯吉恩股份有限公司 分枝杆菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
KR20160130216A (ko) 2014-01-09 2016-11-10 트랜스진 에스아이 헤테로올리고머 미코박테리아 항원의 융합물
US9721484B2 (en) 2014-06-23 2017-08-01 Humanetics Innovative Solutions, Inc. Shoulder kit assembly for crash test dummy
PT3169341T (pt) 2014-07-16 2019-09-09 Transgene Sa Vírus oncolítico para a expressão de moduladores de pontos de controlo imunitário
US10008130B2 (en) 2014-09-17 2018-06-26 Humanetics Innovative Solutions, Inc. Omni-directional shoulder assembly for crash test dummy
US20180028626A1 (en) 2015-02-13 2018-02-01 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016289492B2 (en) 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
RU2758238C2 (ru) 2016-05-12 2021-10-26 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US20190330655A1 (en) 2016-12-28 2019-10-31 Transgene Sa Oncolytic viruses and therapeutic molecules
KR102111244B1 (ko) 2017-02-09 2020-05-15 얀센 백신스 앤드 프리벤션 비.브이. 이종 유전자의 발현을 위한 강력한 짧은 프로모터
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
JP7557738B2 (ja) 2018-10-30 2024-09-30 国立大学法人 東京大学 がん治療のための腫瘍溶解性ウイルス
EP3880243A1 (en) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
WO2021186246A1 (en) 2020-03-19 2021-09-23 Trizell Ltd. Temperature-responsive virus storage system
US20230256057A1 (en) 2020-07-13 2023-08-17 Transgene Treatment of immune depression
WO2022161502A1 (zh) 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 一种靶向蛋白降解系统及其应用
MX2023009738A (es) 2021-02-19 2023-08-30 Janssen Vaccines & Prevention Bv Antigenos de rsv fb prefusion estabilizados.
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CA3260559A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant D protein and a component of TNFSF
CA3261778A1 (en) 2022-08-18 2024-02-22 Transgene CHIMERIC POXVIRUSES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
AU7971194A (en) * 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
FR2711523B1 (fr) * 1993-10-26 1996-02-16 Transgene Sa Procédé de préparation d'un aérosol viral.
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations

Also Published As

Publication number Publication date
ES2187798T3 (es) 2003-06-16
FR2751343B1 (fr) 1998-12-18
AU711409B2 (en) 1999-10-14
JP2000500026A (ja) 2000-01-11
WO1998002522A1 (fr) 1998-01-22
US6451256B1 (en) 2002-09-17
AU3698697A (en) 1998-02-09
EP0853660B1 (fr) 2003-01-22
FR2751343A1 (fr) 1998-01-23
CA2232604C (fr) 2005-06-28
JP3681401B2 (ja) 2005-08-10
DK0853660T3 (da) 2003-05-05
US20030082206A1 (en) 2003-05-01
DE69718612D1 (de) 2003-02-27
DE69718612T2 (de) 2003-11-06
CA2232604A1 (fr) 1998-01-22
EP0853660A1 (fr) 1998-07-22

Similar Documents

Publication Publication Date Title
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
EA200400376A1 (ru) Пептиды, полученные из казеина, и их использование в терапии
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
EP0431129A4 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
ATE319483T1 (de) Verfahren und zusammensetzungen zur selektiven modikation von nukleinsäuren
DE69429260D1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
DE60239394D1 (de) Onkolytische virustherapie
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
FI961536A0 (fi) Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste
DE60009146D1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
ATE298582T1 (de) Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
DK82892D0 (da) Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
ATE292177T1 (de) Gentherapy von lungenkrankheiten
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69231465D1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
DE60040910D1 (de) Inaktivierte zytokine zur immunisierung
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0853660

Country of ref document: EP